The coronavirus disease 2019 pandemic has led to delays in elective and potentially curative surgeries for patients with cT1b-cT2b renal cell carcinoma but research has indicated that surgical delays of up to and beyond 3 months did not result in an increased risk of pT3a upstaging or comprise overall survival.
Maximilian Diehn, MD, PhD, discusses how the use of circulating tumor DNA to analyze minimal residual disease status in patients with lung cancer and other solid tumors is a rapidly developing field with the potential to further personalize treatment decisions about adjuvant therapy.
The oncology community has risen up as a unified front in the battle against coronavirus disease 2019, launching pivotal research efforts to better understand the enemy and collecting data to develop effective therapeutics to fill the treatment arsenal.
The treatment landscape of relapsed/ refractory multiple myeloma has undergone rapid changes over the past 2 decades, with over a dozen drug approvals by the FDA.
Tumor mutational burden has been associated with response to immunotherapy in patients with lung cancer, but there have been various criticisms regarding the validity and routine use of this as a biomarker.
A modified dosing schedule of frontline nivolumab (Opdivo) and ipilimumab (Yervoy) compared with the standard dose showed no differences in responses or safety in patients with advanced renal cell carcinoma, according to results of the CheckMate-920 trial.
A 14-mg dose of lenvatinib showed similar safety to the standard 18-mg dose of the agent, when used in combination with everolimus in the second-line treatment of patients with advanced renal cell carcinoma, but noninferiority could not be confirmed.
Recent research for effective therapies designed to target von Hippel-Lindau disease–associated renal cell carcinoma is pointing to a future with the paradigm that comprises immunotherapy, HIF-2α inhibitors, and potentially CDK4/6 inhibitors.
Combination regimens comprised of immunotherapy and TKI inhibitors have yielded significant benefits in terms of overall survival and progression-free survival with acceptable safety in patients with renal cell carcinoma; however, the cost of these regimens may negate the impact of these advances.
Frontline chemoimmunotherapy trials represent a critical milestone in extensive-stage small cell lung cancer, but one that requires better understanding of the methods that can be used to broaden the patient population in whom durable benefit is currently concentrated.
Tony S. K. Mok, MD, BMSc, FRCPC, FASCO, discusses the actionable mutations that have been identified in the lung cancer space, the agents that have been developed to target them, and the importance of genetic testing to provide personalized care.
Nicholas C. Rohs, MD, discusses the importance of genetic testing in non–small cell lung cancer.
Nabil P. Rizk, MD, MS, MPH, discusses the evolving role of surgery in lung cancer.
Bradley McGregor, MD, discusses the potential utility of the combination of cabozantinib and nivolumab in advanced renal cell carcinoma (RCC).
Toni K. Choueiri, MD, discusses the rationale for the phase 3 COSMIC-313 trial in advanced renal cell carcinoma.
The combination of lenvatinib plus pembrolizumab demonstrated encouraging antitumor activity in patients with metastatic clear cell renal cell carcinoma who had progressed on prior PD-1 or PD-L1 immune checkpoint inhibitor therapy.
Mark E. Robson, MD, discusses how a strong cognizance of germline testing is becoming increasingly important in the field of oncology, across an array of tumor types.
Brian I. Rini, MD, discusses choosing between combinations of dual immunotherapy and immunotherapy/VEGF TKIs in metastatic renal cell carcinoma.
The first-line combination of lenvatinib and everolimus elicited clinical activity in patients with advanced non-clear cell renal cell carcinoma.
Toni K. Choueiri, MD, discusses key findings from the CheckMate-9ER trial in advanced RCC, as well as ongoing trials with the potential to shift the paradigm even further.
Norman E. “Ned” Sharpless, MD, discusses the efforts that The National Cancer Institute has made to combat the coronavirus disease 2019 pandemic.
Clifford A. Hudis, MD, CEO highlights cancer mortality and how it has steadily declined in the United States since 1975.
Targeted agents have restructured the treatment paradigm for patients with advanced hepatocellular carcinoma. The present challenge is to identify the patients most likely to benefit from frontline treatment regimens.
Ursula Matulonis, MD, highlights immunotherapy agents have demonstrated moderate clinical activity for patients with gynecologic cancers, however they fail to yield significant response rates in both the newly-diagnosed and recurrent settings.
Komal Jhaveri, MD, FACP, discusses the importance of outlining the first-line treatment course for patients with HER2-positive breast cancer.
There is still a great deal to learn about the optimal use of BRAF-targeted therapy, as well as immunotherapy, in the adjuvant setting for patients with melanoma.
PARP inhibitors have emerged as a promising therapeutic target in prostate cancer at the 38th Annual CFS® virtual conference.
An explosion of therapeutic options for chronic lymphocytic leukemia has resulted in challenging questions about sequencing therapies for patients who progress after frontline treatment with little data to guide optimal therapy selection.
Frontline treatment decisions for patients with follicular lymphoma can be guided by a general framework; the choice of therapy is often based on several factors such as indications of therapy, bulk of disease, comorbidities, and toxicity.
The treatment landscape for multiple myeloma is poised to enter a new era of innovation with the development of therapies that target B-cell maturation antigen, which is highly expressed on plasma and MM cells.
